Specific activation of the alternative cardiac promoter of Cacna1c by the mineralocorticoid receptor

Specific activation of the alternative cardiac promoter of Cacna1c by the mineralocorticoid receptor

Les antagonistes des récepteurs aux minéralocorticoïdes (MR) appartiennent à l'arsenal thérapeutique pour le traitement de diverses maladies cardiovasculaires, mais les mécanismes conférant leurs effets bénéfiques sont encore mal compris. Une partie de ces effets peuvent être liée à la régulati...

Full description

Bibliographic Details
Main Author:	Ribeiro mesquita, Thássio Ricardo
Other Authors:	Paris Saclay
Language:	en
Published:	2017
Subjects:	Canaux Ca2+ de type L Aldostérone Récepteur aux minéralocorticoïde Cœur Muscle lisse vasculaire L-Type Ca2+ channel Aldosterone Mineralocorticoid receptor Heart Vascular smooth muscle cells
Online Access:	http://www.theses.fr/2017SACLS530/document

Similar Items

Les cibles moléculaires du récepteur minéralocorticoïde dans le coeur
by: Gravez, Basile
Published: (2015)

Le canal calcique de type L, une cible directe de l’aldostérone dans les cardiomyocytes
by: Auguste, Gaëlle
Published: (2015)

Implication de la Lipocaline 2 dans les effets physiopathologiques du récepteur minéralocorticoïde dans le système cardiovasculaire.
by: Tarjus, Antoine
Published: (2014)

Prévention de l'insuffisance cardiaque par l'antagonisation du récepteur des minéralocorticoïdes dans un contexte de syndrome métabolique : une étude intégrative du phénome, du transcriptiome et du miRNOme
by: Youcef, Gina
Published: (2014)

Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis.
by: Mary Elizabeth Moss, et al.
Published: (2015-09-01)

Eight weeks of mineralocorticoid blockade does not improve insulin sensitivity in type 2 diabetes
by: Stine H. Finsen, et al.
Published: (2021-08-01)

Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism
by: Luo Shi, et al.
Published: (2019-11-01)

Aldosterone Inhibits In Vitro Myogenesis by Increasing Intracellular Oxidative Stress via Mineralocorticoid Receptor
by: Jin Young Lee, et al.
Published: (2021-08-01)

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
by: Greg H. Tesch, et al.
Published: (2017-05-01)

Mineralocorticoid receptor antagonist use after hospitalization of patients with heart failure and post-discharge outcomes: a single-center retrospective cohort study
by: Matthew S. Durstenfeld, et al.
Published: (2019-08-01)

Identification et régulation transcriptionnelle des gènes cibles du récepteur des minéralocorticoïdes dans les cellules rénales
by: Le Billan, Florian
Published: (2017)

Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?
by: Line Aas Mortensen, et al.
Published: (2017-11-01)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
by: Yuta Tezuka, et al.
Published: (2021-03-01)

Mineralocorticoid hypertension
by: Vishal Gupta
Published: (2011-01-01)

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015
by: Yu F Osmolovskaya, et al.
Published: (2015-09-01)

Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling
by: Marcondes Alves Barbosa Da Silva, et al.
Published: (2015-10-01)

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
by: S N Tereshchenko, et al.
Published: (2013-12-01)

The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor
by: Rene Baudrand, et al.
Published: (2018-02-01)

The Cardiac Mineralocorticoid Receptor (MR): A Therapeutic Target Against Ventricular Arrhythmias
by: Michel F. Rossier, et al.
Published: (2021-06-01)

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
by: V. N. Soboleva, et al.
Published: (2015-01-01)

Contrôle post-transcriptionnel de l'expression rénale du récepteur minéralocorticoide par les variations de tonicité extracellulaire : conséquences physiopathologiques.
by: Lema, Ingrid
Published: (2016)

Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses
by: Fernet M, et al.
Published: (2018-09-01)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
by: Marie Pieronne‐Deperrois, et al.
Published: (2021-06-01)

Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
by: Tomaschitz Andreas, et al.
Published: (2012-09-01)

Effects of chronically high levels of aldosterone on different cognitive dimensions: an investigation in patients with primary aldosteronism
by: Lukas Engler, et al.
Published: (2019-04-01)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
by: Yugar-Toledo JC, et al.
Published: (2017-10-01)

Cardiac Mineralocorticoid Receptor and the Na+/H+ Exchanger: Spilling the Beans
by: Irene Lucía Ennis, et al.
Published: (2021-01-01)

Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease
by: Stefania Gorini, et al.
Published: (2018-09-01)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
by: Stephen eOrena, et al.
Published: (2013-10-01)

The tubulogenic effect of aldosterone is attributed to intact binding and intracellular response of the mineralocorticoid receptor
by: Minuth Will, et al.
Published: (2007-09-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
by: A. M. Esayan, et al.
Published: (2018-04-01)

Hyperglycemia Potentiates Prothrombotic Effect of Aldosterone in a Rat Arterial Thrombosis Model
by: Anna Gromotowicz-Poplawska, et al.
Published: (2021-02-01)

SOME ASPECTS OF STEROID REGULATION IN TELEOSTS
by: Nikolai Rendakov
Published: (2018-06-01)

Aldosterone Blocks Rat Stem Leydig Cell Development In Vitro
by: Jingwei Zhang, et al.
Published: (2018-01-01)

The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial)
by: Line Aas Mortensen, et al.
Published: (2018-05-01)

Sexual Dimorphism of Corticosteroid Signaling during Kidney Development
by: Margaux Laulhé, et al.
Published: (2021-05-01)

Mineralocorticoid Receptor Signaling Contributes to Normal Muscle Repair After Acute Injury
by: J. Spencer Hauck, et al.
Published: (2019-10-01)

Implication de l'aldostérone dans les changements hémodynamiques de la grossesse
by: Provencher, Mylène
Published: (2012)

Implication de l'aldostérone dans les changements hémodynamiques de la grossesse
by: Provencher, Mylène
Published: (2012)

Salidroside contributes to reducing blood pressure and alleviating cerebrovascular contractile activity in diabetic Goto-Kakizaki Rats by inhibition of L-type calcium channel in smooth muscle cells
by: Yu-Guang Ma, et al.
Published: (2017-04-01)